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Association of Epstein-Barr Virus with Nasopharyngeal Carcinoma and Current
Status of Development of Cancer-derived Cell Lines
Charles Gullo,1BS, PhD, Wong Kein Low,2MBBS, MMed, FAMS, Gerrard Teoh,3,4MBBS, MMed, FAMS
Introduction
Although nasopharyngeal carcinoma (NPC) has been
reported in almost all parts of the world, most cases of NPC
are found in South East Asia, Southern China (including
Hong Kong), North Africa and in the Eskimo population of
Alaska, USA.1-3 For reasons that still remain unclear, the
Chinese are more susceptible to NPC than other races.4
Earlier studies have suggested that dietary habits could be
major contributors to the pathogenic process. These include
the ingestion of salted fish and preserved food.5,6 High-risk
areas include southern China, Tunisia and Greenland,
where the diet contain large amounts of N-
nitrosodimethyamine (NDMA), N-nitrospyrrolidene
(NPYR) and N-nitrospiperidine (NPIP),7 common
ingredients found in salted fish and preserved food.
Moreover, environmental factors may also contribute to
the development of NPC. For example, exposure to smoke
or chemical pollutants, including trace elements (e.g. nickel)
have been reported to be associated with the development
of NPC.8 A recent study suggests that among occupational
hazards such as exposure to smoke, construction, metal,
wood dust, motor fuel and oil, paint and varnishes etc., only
wood dust was statistically significant for the development
of NPC.9 Therefore, the development of NPC disease is
multi-factorial with genetics, diet, and environmental
exposure all playing large roles.
NPC Histological Subtypes
The World Health Organization (WHO) classifies NPC
into 3 varieties. Type I or squamous cell carcinoma (SCC)
is seen in 25% of cases of NPC. These tumours produce
keratin and demonstrate the presence of intracellular bridges
when observed under the electron microscope.
Approximately 20% of NPCs are of the Type II or non-
keratinising carcinoma (NKC) variety. Tumour cells of the
NKC phenotype demonstrate a range of cellular
morphologies, from mature to anaplastic cells. Finally,
Type III or undifferentiated carcinoma (UC) NPC constitutes
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Abstract
It is well known that the Epstein-Barr virus (EBV) contributes directly to tumourigenesis in
nasopharyngeal carcinoma (NPC), primarily in the undifferentiated form of NPC (WHO type
III; UNPC or UC), which is commonly found in South East Asia. Unfortunately, research in NPC
has been severely hampered by the lack of authentic EBV-positive (EBV+) human NPC cell lines
for study. Since 1975, there have been more than 20 reported NPC cell lines. However, many of
these NPC-derived cell lines do not express EBV transcripts in long-term culture, and therefore
that finding may dispute the fundamental theory of NPC carcinogenesis. In fact, currently only
one EBV+ human NPC cell line (C-666) in long-term culture has been reported. Hence, most of
the NPC cell lines may not be representative of the disease itself. In order to better understand
and treat NPC, there is an urgent need to develop more EBV+ human NPC cell lines. In this
review, we discuss the authenticity of existing NPC cell lines and the impact of our understanding
of NPC biology on the treatment of the disease and the relationship of EBV to NPC in the context
of cell lines.
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the bulk (55%) of the tumours seen in patients with NPC.10
Since there is no uniform morphological characteristic of
NPC-affected tissues, diagnosis of UC NPC is usually
based on the location of the tumour in the nasopharynx and
the presence of EBV transcripts in the tumour cells. The
EBV genome is found in transformed epithelia cells but not
in lymphocytes. Clonal EBV genome is present in the early
preinvasive dysplastic lesion or carcinoma in situ; indicating
that infection of EBV precedes the development of
malignant invasive tumour.11
Geographical Distribution of NPC subtypes
The distribution of NPC subtypes in certain geographical
areas of the world does not necessarily conform to the
overall worldwide distribution of NPC subtypes according
to the WHO classification above. For example, in the
regions where NPC is most prevalent, i.e. South East Asia,
Southern China and Hong Kong, there is a predilection for
UC NPCs. For example, most (85%) NPCs found in
Singaporean Chinese are classified as UCs; and the
incidence is greater among childhood and adolescent
patients.12 In contrast, most NPCs in Western countries
(e.g. USA) are SCCs and thought to be related to the use of
tobacco.13,14 These differences contest the applicability of
Western data and studies on Eastern populations, and vice
versa. Derivations of cell lines from Eastern populations
are limited and should be established based on the above
findings.
The role of EBV in the pathogenesis of NPC
EBV
Epstein and his group discovered novel viral particles
within cultured cells from patients with Burkitts’s lymphoma
in 1964,15 and 4 years later; this new virus was named EBV.
EBV is a relatively large gamma herpesvirus, and its DNA
is double stranded and approximately 172 kilobases (kb) in
length.16 Approximately 90% of the adult population
throughout the world are EBV-positive by serology.
Elevated titers of IgA antibody to EBV viral capsid antigen
(VCA) are usually found in patients with NPC, therefore
this method of measuring patients’ EBV-specific IgA
antibodies is useful in screening for early detection of
NPC.2 EBNA1 and EBERS are expressed in all EBV-
positive cases of NPC and LMP1 is present in up to
approximately 65% of cases.17,18 In almost all cases of EBV
infection, the oropharynx is the primary site of infection, as
well as the site of viral replication. Epstein-Barr virus is
known to target primarily B-lymphocytes. In vitro studies
demonstrate that EBV infects and potentially activates B
cells by binding to the type 2 complement receptor (CR2,
or CD21), the putative EBV receptor.16 Hence, EBV appears
to home to the oropharynx, and more specifically, the B
cells within the oropharynx. The strain B95-8 can be found
in EBV-positive cell lines such as Raji, Namalwa, and CA
46.19 These cell lines are all of B-lymphocyte lineage. This
strain has been used as a benchmark in order to check for
EBV positively in NPC. The EBV latent proteins include
the 6 nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C, and
EBNA-LP) and the 3 latent membrane proteins (LMPs 1,
2A, 2B). EBNA-LP is transcribed from variable numbers
of repetitive exons. LMP2A and LMP2B are composed of
multiple exons located on either side of the terminal repeats
(TR) region, which is formed during the circularisation of
the linear DNA to produce the viral episome. EBER1 and
EBER2 are highly transcribed nonpolyadenylated
RNAs and their transcription is a consistent feature of
latent EBV infection.
EBV and NPC
It was in 1966 that Old et al first discovered the relationship
between Epstein Barr virus and NPC, using in situ
hybridisation and the anticomplement immunofluorescent
(ACIF) assay.20 Subsequent studies by others demonstrated
the expression of EBV latent genes – Epstein-Barr virus
nuclear antigen (EBNA), latent membrane protein-1 (LMP-
1), LMP-2 and Epstein-Barr virus encoded small RNAs
(EBER) – in NPC cells16 confirming the infection of
tumour cells by EBV. Intriguingly, expression of EBV
early antigen (EA) is positively correlated with the
consumption of salted and preserved food, suggesting that
development of EBV-positive NPC could be related to
dietary habits21 and provides another link to the
epidemiological studies with NPC. Future studies should
consider the effects of dietary risk factors on the risk of
specific histologic subsets of NPC, and not assume that the
disease is aetiologically homogeneous.  Since EBV infection
indeed precedes clonal expansion of malignant cells,22
EBV is thought to contribute, at least in part, to the overall
pathogenesis of NPC. Many studies have shown that
undifferentiated nasopharyngeal carcinomas (UNPC) are
invariably EBV-positive, regardless of geographical
origin.13,23,24
The process of EBV entry into keratinocytes and NPC
cells is more complex, as both keratinocytes and NPC cells
express only low levels of CR2 receptor.25 In addition, the
relevance of serological tests for EBV infection in predicting
the occurrence of NPC is presently still unclear. Specifically,
a positive serological test for EBV EA26 may be found in
greater than 80% of patients with NPC in Singapore,27 yet
many normal individuals also express a positive EBV EA
serological test, and never develop NPC. The procedures
that researchers have carried out, such as PCR, revealed
expression of the LMP2A and LMP2B genes and of latent
transcripts running through the BamHI A region of the
EBV genome in the opposite direction to the conventional
lytic cycle mRNAs transcribed over this region.28,29 The
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BamHI A transcripts have also been detected in other EBV
associated tumours such as Burkitt’s lymphoma and
Hodgkin’s lymphoma.30,31 Analysis using western blot
suggested a latent EBV infection in UNPC, and the
expression of BZLF1 has been reported in some cases,32
although the tumour cells do not seem to be fully permissive
for virus replication. These findings are difficult to reconcile
with the frequent detection of antibodies against structural
viral proteins in the sera from patients with UNPC; especially
patients with UNPC have raised IgA antibody titers to the
VCA, EA, and MA complexes.2 The rise in IgA titres to
these antigens can be noticed before the development of
UNPC and correlates with tumour burden, remission and
recurrence.33,34 Recently, a group in Taiwan used an animal
model to carry out functional analysis of EBV in NPC cells.
Their results showed that EBV-positive tumours grew
faster than EBV-negative tumours, and also had clonal
EBV terminal repeat sequences. Furthermore, EBV up
regulates host genes only in cells that express those genes
but not in cells that do not express them.35 All these studies
have unfortunately been greatly hampered by the lack of
authentic EBV+ NPC cell lines, and little more is known
about the mechanisms of entry of EBV, and the growth and
survival NPC cells. In fact, numerous cell cultures that
were initially positive for EBV eventually lost EBV
expression after prolonged cell culture.
EBV Activation of Anti-apoptotic and Cell Proliferation
Pathways in NPC
NPC is consistently associated with Epstein-Barr virus
(EBV) infection. EBV-encoded LMP1, expressed in most
of NPC, has been suggested to have an important role in the
pathogenesis and development of NPC and its expression
correlates with poor prognosis. LMP1 molecules aggregate
in the cell membrane and through 2 C-terminal activating
regions, interact with TNF receptor associated factors
(TRAFs) and TNF receptor associated death domain protein
(TRADD).36-38 In vitro, LMP1 expression in epithelia cells
can upregulate the expression of intercellular adhesion
molecule 1 (ICAM-1), CD40, and cytokines such as
interleukin 6 (IL-6) and IL-8.39,40 LMP1 also can induce the
expression of CD70 antigen, a member of the TNF family,
in epithelial cells in vitro.17,41 LMP1 can induce a matrix
metalloproteinase, MM-9, through C-terminal activating
regions 1 and 2 (CTAR-1 and CTAR-2), an effect blocked
by overexpression of inhibitor of nuclear factor kappa B
(IκB).42 LMP1 encoded by EBV is a membrane protein that
activates multiple signalling pathways and transcription
factors, including Nuclear Factor-kappaB (NF-κB). NF-
κB activation is necessary for Hodgkin/Reed-Sternberg
(HRS) cells to proliferate and inhibit apoptosis.43
Furthermore, activation of NF-κB is essential for B-cell
immortalisation by EBV and LMP1-mediated
transformation of fibroblasts.44,45 EBER-negative Hodgkin
Lymphoma (HL) also displays constitutive NF-κB
activation, indicating that without LMP1, other mechanisms
exist to activate NF-κB. LMP1 has been shown to activate
the mitogen activated protein kinase pathways and Janus
kinase (JAK) signal transducers and activators (STATs) of
transcription pathway in epithelia cells, as well as in B
cells.46 LMP1 and 2A also activate the phosphatidylinositol
3’-OH kinase (P13K)/Akt pathway, which is commonly
activated inappropriately in malignancy.47 A recent study
showed that P13K/Akt pathway was of importance in NPC
pathogenesis. P13K/Akt pathway activation with
subsequent phosphorylation and inactivation of GSK-3β
and nuclear β-catenin accumulation were characteristic of
primary NPC specimens.47 Thus it is clear that NPC uses its
viral proteins to activate numerous cellular pathways in the
NPC tumour that results in proliferation and prevents the
transformed cells from dying.
The B Specific Properties of the Viral Genes of EBV
Primary EBV infections occur early in life and in most
individuals it is asymptotic. In vitro, EBV readily infects
resting peripheral blood B cells that express the EBV
receptor, CD21, resulting in latent infection and
proliferation. The Lymphoblastoid cell line (LCL) is an in
vitro model of transformed B cells (B cells that are infected
by EBV). The LCL carries many copies of the EBV viral
genes in an episomal fashion and constantly expresses a
limited set of viral gene products consisting of latent
proteins, (6 nuclear antigens; EBNAs 1, 2, 3A, 3B, 3C and
–LP and 3 latent membrane proteins; LMPs 1, 2A and
2B).45  LCLs expressed high level of B cell activation
markers CD23, CD39, and CD70, and of the cellular
adhesion molecules LFA1 (CD11a/18), LFA3 (CD558)
and ICAM1 (CD54).48 These markers are induced to high
levels when the B cells are activated by antigenic or
mitogenic stimulation, suggesting that EBV-induced
immortalisation can be brought out through the constitutive
activation of the similar cellular pathways that result in
physiological B-cell proliferation.49 The EBNA1 protein
binds to viral DNA and allows the EBV genome to be
maintained in the B cells as a circular DNA episome.50
EBNA-2 upregulates the expression of LMP 1 and LMP2,
as well as cellular proteins that contribute to the growth and
transformation of B cells.51 LMP-1, which acts as an
oncogene,52 mimics the constitutively active form of the B-
cell surface molecule CD40 inducing a CD40 signalling
response.53 It also upregulates the expression of the
antiapototic proteins (e.g. Bcl-2 and A20)54 and results in
cytokine production (e.g. IL6 and IL8).40,55 Thus, viral
proteins confer strong pro-survival signal to EBV infected
cells of the B cell lineage. LMP-1 also mimics the functions
of the members of the tumour necrosis factor receptor
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(TNFR) family, activating a number of signalling
pathways in a ligand independent manner.56 Many of
these downstream pathways result from the ability of
TNFR- associated factors (TRAFs) to interact either directly
with CTAR1 or indirectly via the death domain protein
TRADD to CTAR2.45 The binding of TRAFs to the
cytoplasmic tails of LMP1 provides a platform for the
assembly and activation of upstream signalling molecules
including non-receptor tyrosine kinases.57,58 However, since
NPC is a result of infection of the epithelia, EBV LCL
biology may not be representative of the Biology of EBV
in NPC itself.
Thus, Epstein-Barr virus (EBV) infection in vitro causes
transformation of B cells and can result in the generation of
B lymphoblastoid cell lines. These cells have been useful
as tools for 1) raising cell-mediated immunity (both CD4+
and CD8+ T cells) against EBV, 2) diagnostics of genetic
metabolic disorders, 3) understanding EBV pathogenesis
and 4) interrogating B cell biology (e.g. CD40 and CD40L
signalling). Although there are many similarities between
EBV/LCL and EBV/NPC tissue or cell lines there are some
notable differences. One important difference is that whereas
LCLs constitutive express of a small number of EBV-
coded latent proteins, the nuclear antigens EBNA 1, EBNA
2, EBNA 3 and EBNA-LP and the latent membrane
protein (LMP), tissue biopsies from EBV/NPC shows
no expression of EBNA 2, EBNA 3 or EBNA-LP.18
Furthermore, none of the biopsies studied expressed
any of the EBV lytic cycle antigens. Another major
difference is the cell of origin for EBV infection. The
strongest links between the association of EBV and
human cancer is the undifferentiated nasopharyngeal
carcinoma which is of epithelial origin while LCLs
are universally B cells. The tissue tropism is not defined
by the receptor for EBV as CR2 is also believed to be the
EBV receptor for B cells as well.59 However, the immune
properties such as CD40-CD40L interactions as well as the
mode of EBV viral gene maintenance in the B cells are
likely to play significant roles in the observed differences
between epithelial cell EBV/NPC and B cells EBV/LCL
EBV pathogenesis.
Authentic EBV+ Human NPC Cell Lines
Today there are only limited numbers of authentic EBV-
positive NPC cell lines in existence. HONE-1 C40 (subclone
of HONE-1),60,61 which has maintained EBV-positively up
to 42 passages and contains 85% to 90% EBV nuclear
antigen (EBNA)-positive cells may be an example of an
authentic NPC cell line. Other examples include CG-162
and C-66663 that have been shown to maintain EBV
positively in long-term culture. The authenticity of these
cell lines is complicated due to the fact that the EBV
genome is lost in many cell lines after long-term culture.
Original Tissue Used for Cell Line Development
In general, tissues from 2 sites from NPC patients have
been used establish long-term cell lines. Most of the cell
lines have been derived from primary tumour tissue samples
obtained from the nasopharynx, e.g. CNE-1,1 CG-1,62 and
C1564 (Table 1). A number of cell lines were also derived
from metastatic NPC tissue from other sites. For example,
the NPC-BM1 cell line was established from bone marrow
biopsy sample in a patient with bony metastases and the
C17 cell line was derived from a skin biopsy sample in a
patient who had skin, bone and liver metastases and C18
cell line, from a cervical lymph node biopsy in a patient
with locally advanced tumour with regional lymph node
involvement.
Short-term EB positive NPC-derived Cell Lines
Several cell lines have been derived from UC and poorly
differentiated SCC NPC tissue (the most common subtypes
of NPC tissue found in the South East Asia, South China
and Hong Kong) that were initially EBV-positive (Table
1). These include: UC derived C-15, C-17, C-18, C666-1
(HK666), CAO, CG 1, CNE-2, CNE-2Z, CNE-3, HNE-1,
HONE-1, NPC/HK2117 (Xeno-1), NPC/HK1915 (Xeno-
2), NPC/HK1530 (Xeno-3), NPC-TW03, NPC-TW 06,
NPC-TW07, SUNE and SUNE.60-76 Other cell lines were
also derived from the less common EBV+ SCC NPC tissue,
including NPC-TW 01 (a.k.a. NPC-TW 039), NPC-TW
05, and NPC-TY861.70,71,77,78 The limitation of these cells
lines are that they have become EBV-negative after
prolonged culture, thus their physiological relevance is
uncertain. By 1989, only 3 permanent epithelioid NPC cell
lines were established, CG1 and CNE2 (from China), and
NPC/HK1 (from Hong Kong). Again, none of these NPC
cell lines contained the EBV genome despite extensive
testing; further suggesting that either EBV infection was
unrelated to the development of NPC; or that these cell
lines were not representative of NPC tissue or both. CG-1
and CNE were both EBV-positive but after long-term
culture they lost their EBV positivity.79
EBV Negative NPC-derived Cell Lines
In contrast to the initially EBV+ tumour tissue, several
NPC-derived cell lines were generated from EBV-
tumour tissue. These included those derived from
well-differentiated SCCs – CNE, NPC/HK1, NPC-TW 02
(NPC-TW 076), and NPC-TW 08.70,71,77,80-82 Second
generation NPC-derived cell lines were occasionally
produced from the parental cell line. For example, the
CNE epithelioid NPC cell line subsequently produced
the CNF fusiform cell line. Importantly, neither CNE nor
CNF cell lines demonstrated the presence of EBV virus
particles,82 again challenging a causal relationship between
EBV and NPC.
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Attenuation of EBV Expression in Long-term NPC-de-
rived Cell Lines
Expression of EBV DNA has been observed to become
attenuated after longer-term culture in many cell lines,
including NPC-TW 01, NPC-TW 03, NPC-TW 05, NPC-
TW 06, and NPC-TW 07, etc. suggesting that EBV does
not seem to be required for the survival and proliferation
(Table 1).60,71,81,82  In other words, EBV might facilitate the
initiation of the pathological process that eventually leads
to NPC, but is not required for subsequent growth of
tumour cells in vitro. Currently, this issue cannot be resolved
since there is a lack of EBV+ NPC cell lines that are truly
Table 1. Long-term Solid Tissue Cultures Derived from NPC Tumours
Cell line NPC WHO EBV References
classification Derived cell type Culture method status
C-15 NKC epithelial/syncytial subcutaneous xenografting /Swiss nude mice IP (64)
C-17* NKC epithelial/syncytial subcutaneous xenografting /Swiss nude mice IP (64)
C-18† NKC epithelial/syncytial subcutaneous xenografting /Swiss nude mice IP (64)
CAO — — xenografting in nude mice IP, LP (68)
X666 UC epithelial/syncytial subcutaneous xenografting a in BALB/c IP, LP (90)
(nu/nu) athymic nude mice
C666 UC epithelial/syncytial RPMI 1640, 1% fetal bovine serum (FBS) IP, LU (67,90)
C666-1; HK666 UC epithelial/syncytial RPMI 1640, 1% FBS IP, LP (63,67)
CG1 NKC epithelia DMEM/F12, 5% FBS IP (62)
CNE-2 UC epithelial RPMI 1640, 10% FBS IP (72)
CNE-2Z UC epithelial RPMI 1640, 10% FBS IN (76)
CNE-3 UC epithelial RPMI 1640, 10% FBS IN  (65)
HNE-1 UC epithelial DMEM/F12 IP, LN (60,61,74)
HONE-1 UC epithelial RPMI 1640 IP, LN (60,61,74)
NPC/HK1530; Xeno-3 UC epithelial subcutaneous xenografting in athymic mice IP, LN (69)
NPC/HK1915; Xeno-2 UC epithelial subcutaneous xenografting in athymic mice IP, LN (69)
NPC/HK2117; Xeno-1 UC epithelial subcutaneous xenografting in athymic mice IP, LN (69)
NPC-TW 03 UC epithelial DMEM, 5% FBS IP, LN (70,71)
NPC-TW 06 UC epithelial DMEM, 5% FBS IP, LN (70,71)
NPC-TW 07 UC epithelial DMEM, 5% FBS IP, LN (70,71)
SUNE UC epithelial RPMI 1640, 10% FBS IP (66)
SUNE1 UC epithelial DMEM, 5% FBS UNK (14)
NPC-TW 04 UC epithelial DMEM, 5% FBS IN, LN (70,71)
NPC-TW 09 UC epithelial DMEM, 5% FBS IN, LN (70,71)
CNE SCC epithelial RPMI1640, 15% FBS IN, LN (80,82)
NPC/HK1 SCC epithelial RPMI1640, 15% FBS IN, LN (81)
NPC-TW 02; 076 SCC epithelial DMEM, 7% FBS IN, LN (71,77)
NPC-TW 08 UC epithelial DMEM, 5% FBS IN, LN (70,71)
NPC-TW 01; 039 SCC epithelial DMEM, 7% FBS IP, LN (71,77)
NPC-TW 05 UC epithelial DMEM, 5% FBS IP, LN (70,71)
NP69SV40T SCC epithelial Immortalised by SV40T IP, LP (46)
NP39E6/E7 SCC epithelial Immortalised by HPV16E6/e7 IP, LP (46)
NPC-BM1‡ UC epithelial RPMI1640, 10% FBS UNK (91)
NPC-F/L UC epithelial EF-10, 10% FBS, co cultivated IP, LP (85)
with EBV-transformed cell line.
IN: initially EBV-negative; IP: initially EBV-positive; LN: long-term culture EBV-negative; LP: long-term culture EBV-positive; LU: long-term culture
EBV-status unknown; NKC: non-keratinising carcinoma; SCC: squamous cell carcinoma; UC: undifferentiated carcinoma; UNK: unknown.
* Derived from metastatic tissue in the skin
† Derived from metastatic tissue in the regional lymph node
‡ Derived from metastatic tissue in the bone marrow
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representative of NPC itself.
Development of NPC-derived Cell Lines Using Xenografts
Several cell lines have been derived from transplantation
of a human source to an animal one. NPC-derived cell
lines; C15-C18 was subcutaneously xenografted into Swiss
nude mice. X666 was derived from asubcutaneous xenograft
of BALB/c (nu/nu) athymic nude mice. NPC/HK1530
(Xeno3), NPC/HK1915 (Xeno2) and NPC/HK2117
(Xeno3) were all derived from athymic murine xenografts.
The CAO NPC cell line was an EBV-positive NPC-
derived from a 54-year-old male patient from Shanghai
China and was propagated in a BALB/c nude mouse.83,84
Again, since these cell lines are not derived from primary
cultures, the relationship to NPC itself is controversial.
Development of NPC-derived Cell Lines Using Other
Methods
Currently there are hybrid tumour cells known as NPC-
F/L that have been developed.85 These were made using a
co-culture system in which EBV transformed LCL of
adenoid origin was cultured in the presence of NPC tissue.
NPC-F/L contains some EBV genome such as the EBNA
and EA but do not have VCA. In another method, the SCC
derived EBV-positive cell epithelia squamous cell
carcinoma NP39E6/E7 was generated by immortalisation
with HPV16E6/E7 and NPC cell line NP69SV40T, was
immortalised by SV40LT Ag.46 These 2 methods, however,
may not be truly representative of the biological properties
of NPC, as they are not from pure primary culture.
Difficulties in Culturing NPC Cells In vitro
Limited Tissue Quantity from PNS Biopsies
There are many inherent limitations to culturing NPC
cells in vitro. Typically, PNS biopsies provide only small
tissue fragments. In order to increase the amount of available
tissue, subcutaneous tumours may be first transferred to
athymic mice for initial in vivo expansion before seeding
into tissue culture flasks for in vitro culture.63 Besides the
potential introduction of murine cells, this method is likely
to result in changes to the primary human biopsy tissue
sample.
Contamination by Other Cell Types
It is common for biopsy tissues to be heavily infiltrated
with lymphoid cells and cells of connective tissue origin.
Hence, it is virtually inevitable that cell lines established
from tumour explants acquire a lymphoblastoid phenotype
during the initial stages of long-term cell culture.67 Several
investigators have used serum free medium (SFM) to
inhibit the fibroblast/mesenchymal cell growth and promote
tumour cell proliferation, e.g. the NPC-TW039 and NPC-
TW076 cell lines.77 Established NPC-derived cell lines
were later converted from SFM to complete medium
containing foetal bovine serum (FBS). This may also have
a dual benefit of helping to decrease the serum dependent
loss of EBV status.77 Other investigators have used pipetting
during cell culture to remove fibroblasts; i.e. the CG-1
NPC-derived cell line.62 There have been many limitations
in culturing these cell lines. The following are some problems
encountered when trying to establish an EBV-positive
NPC cell lines. Firstly, there are not many true EBV-
positive NPC cell lines available that can be used as a
standard for the development of other NPC cell lines with
the only exception of C-666.63 However, its status as a true
NPC cell line remains questionable. Secondly, the cultures
lose their EBV- positively after long periods of in vitro
culture. Transplantation into nude mice of NPC material
has not been very efficacious and most of the primary
transplanted tumours are no longer available for further
investigation.64 Moreover, it is best if a tumour is obtained
directly from primary tissue rather than from another
source such as from xenograft or transformed EBV+ cell
lines. This provides a more accurate reflection of the
cytogenetic details of the primary tumour and thus is a
better tool for study of NPC tumourigenicity.
Conclusion
Here we have presented the importance of using authentic
EBV+ human NPC cell lines for research in NPC.
Specifically, continuous cell lines are important tools for
the study of the genetic mechanisms and environmental
factors responsible for NPC, both in terms of
tumourigenicity as well as its metastatic potential. Although,
there were many NPC cell lines that have been established
using numerous culture methods, most of them are EBV-
negative after a long-term culture. Carcinomas with similar
features to UNPC have been described at other sites
including the thymus, tonsils, lungs, stomach, skin or
cervix, and are often referred to as undifferentiated
carcinoma of nasopharyngeal type (UCNT).86 Some of
these carcinomas showed less strong EBV-positively, such
as those derived from thymic epithelia tumours from Chinese
but not western patients.87
The precise mechanism by which EBV transforms cells
is becoming clearer as more research is conducted. The
viral gene expression in EBV-associated tumours is limited
to a few latent genes of which the most prevalent is LMP1.
It is reported to act as a constitutively activated receptor that
causes aberrant cellular signalling to at least 4 major
pathways. The role for virus in the pathogenesis of NPC is
still largely circumstantial and controversial.88 For example,
the squamous cell NPCs and non-keratinising NPCs vary
in their degree of EBV association. Squamous cell NPCs
may in fact be EBV-negative and other factors such as
smoking or HPV infection may be more relevant in the
September 2008, Vol. 37 No. 9
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pathogenesis of these cell types. On the other hand, non-
keratinising NPCs are almost always EBV-positive,
suggesting that the virus is a rate-limiting step for these
tumours. It will be important to define the exact timing of
EBV infection of nasopharyngeal epithelial cells and to
identify the factors that precede and probably pave the way
for EBV infection. Clearly, further studies are required to
support these findings. The complexity of these virus and
host relationships suggests the existence of potential targets
for gene therapy for EBV-related cancers.
The geographically constrained distribution of EBV
associated NPC in Southeast Asian populations suggests
that both viral and host genetics may influence disease risk.
The analysis of LMP1 with reference to the geographical
distribution demonstrate that LMP1 sequences show a
distinct geographic structure, indicating that the southeast
Asian isolates have evolved as a lineage distinct from those
of Papua New Guinea, African, and Australian isolates.89
Due to the fact that NPC occurs more frequently in Asia
than compared to the Western regions, there is increased
motivation in establishing NPC cell lines from each region.
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